RIBOLIFE-B (06938) intends to acquire 25.93% of the equity interest in Xingborun, increasing its shareholding to approximately 88.17%.

RIBOLIFE-B (06938) Announcement: On June 30, 2026, our company (as the buyer) entered into an equity transfer agreement with the Haihe Asymchem Laboratories Fund (as the seller). Our company has conditionally agreed to acquire, while the seller has conditionally agreed to sell, 25.93% equity of Xingborun at a total price of 70 million RMB. According to the capital increase agreement, the Haihe Asymchem Laboratories Fund has been granted redemption rights, allowing them to request redemption of their equity in Xingborun in the event of a designated redemption event. The acquisition was conducted through fair negotiation between both parties, with the company expressing the intent to redeem and the Haihe Asymchem Laboratories Fund agreeing, and the price was determined according to the redemption price mechanism specified in the capital increase agreement. Additionally, based on the valuation of approximately 11.5102 RMB per share of registered capital at the price of 1.00 RMB per share in the most recent round of equity financing conducted by Xingborun, the corresponding valuation of 25.93% equity of Xingborun is approximately 74.8163 million RMB, which is higher than the price paid. Our company is a clinical-stage biopharmaceutical company specializing in the development of nucleic acid therapy, primarily focusing on siRNA drugs. Xingborun is our company's direct non-wholly owned subsidiary involved in the production of phosphoramidites and nucleoside products, serving as an important upstream production and industrialization platform within our group. Xingborun has begun mass production and external sales, with its business continuously growing. Upon completion of the acquisition, our company's equity in Xingborun will increase from approximately 62.24% to around 88.17%, strengthening our control over Xingborun and enabling our company to receive a larger share of the economic benefits and future returns generated by Xingborun.